In terms of combining IO102-IO103 with immune checkpoint inhibition, such as the PD-1 antibody pembrolizumab in our phase 2 trial that I presented at ESMO, the rationale is that subcutaneous injection ...
E+P continues to have a comparable safety profile to pembrolizumab alone other than injection site reactions as expected with ...
CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy ...
No DLTs were observed with repeated intratumoral injections of BT-001 alone (in 18 patients) or in combination with pembrolizumab (in 6 patients). - Oncolytic virus BT-001 was shown to replicate and ...
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...
An experimental mRNA cancer vaccine shows promising results in a Phase 1 trial, potentially offering new hope for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback